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Abstract
Eight new cardiac glycosides/aglycones (antiaritoxiosides A–G, 1–7, and antiarotoxinin B, 8), two 
new coumarins (anticarins A–B, 41–42), and two new flavanones (antiarones L–K, 43–44) were 
isolated from trunk bark of Antiaris toxicaria together with 53 known compounds. The new 
structures were established by extensive analysis of spectroscopic data. Compound 1 (10-carboxy 
and 3α-hydroxy) and compounds 3–6 (10-hydroxy) contain unique substituents that are rarely 
found in cardiac glycosides. The cytotoxic effects of isolated compounds against ten human 
cancer cell lines, KB, KB-VIN, A549, MCF-7, U-87-MG, PC-3, 1A9, CAKI-1, HCT-9 and S-
KMEL-2, were tested using the sulforhodamine B assay. Five compounds (12, 16, 20, 22, and 31) 
showed significant cytotoxicity against all ten cancer cell lines, with notable potency at the ng/mL 
level against some cell lines, which merits further development as clinical trial candidates.
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1. Introduction
Cardiac glycosides are naturally occurring compounds with a steroidal framework and are 
used for the treatment of congestive heart failure and as anti-arrhythmic agents. They also 
have been used as arrow poisons, abortifacients, emetics, diuretics, and heart tonics.1 
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Mechanistically, their anti-arrhythmic activity results from inhibition of Na+/K+-ATPase, 
and leads to an increased intracellular calcium concentration. Recent research indicated that 
binding of cardiac glycosides to Na+/K+-ATPase can activate multiple downstream signal 
transduction pathways that regulate many important physiological and pathological states.2 
Less well known are the emerging role of this compounds category in the prevention and/or 
treatment of proliferative diseases, such as cancer. Because cardenolide-like compounds are 
often quite toxic, however, the potential use of such compounds for the treatment of cancer 
was abandoned 40 years ago. Even so, studies have revealed that some cardiac glycosides 
can selectively inhibit human tumor cell growth, but not normal cellular proliferation 
through complex cell signal transduction mechanisms.1 Specifically, cardiac glycosides can 
inhibit growth of cancer cells, induce apoptosis via activation of caspase-3, induce 
cytochrome C release from mitochondria, and generate reactive oxygen species. In addition, 
clinical trials of cardiac glycosides and extracts containing them have been initiated to assess 
the anticancer potential.2 Therefore, the use of certain cardiac glycosides may represent a 
worthwhile approach for control of cancer, despite their narrow therapeutic index.
In a previous investigation of bioactive compounds with potential therapeutic value, we 
reported cardiotonic principles from Antiaris toxicaria (Pers.) Lesch.3 As a continuation of 
our anticancer research program based on natural products, an ethanolic extract of A. 
toxicaria (Moraceae) was found to show significant cytotoxicity against KB cells. A. 
toxicaria, also called ‘upas tree’, is widely distributed in tropical rain forests of Southeast 
Asia. Phytochemical studies have shown that this plant contains cardiac glycosides,3,4 
prenylaurones,5 chalcones,6 flavanones,6 and dihydrochalcones.7 Prior investigations also 
indicated that this species exhibited a broad spectrum of biological activities, such as anti-
tumor,8–12 anti-arrhythmic,3 and 5-lipoxygenase inhibition effects.12 Therefore, an intensive 
investigation of this cytotoxic extract was carried out and led to the isolation of 12 new 
compounds, together with 53 known compounds. Herein, we describe the isolation, 
structural elucidation, and antitumor activity of these isolates against ten human cancer cell 
lines. Preliminary structure–activity relationship (SAR) correlations are also described. In 
addition, based on the structures of 10-hydroxy-19-nor-cardenolides and 19-nor-
cardenolides identified from this plant, a biogenetic pathway of cardiac glycoside has been 
proposed.
2. Results and discussion
Twelve new compounds, including eight cardiac glycosides/ aglycones (1–8), two 
coumarins (41–42) and two flavanones (43–44) (Fig. 1), together with 53 known 
compounds, were isolated from an EtOH extract of fresh trunk bark of A toxicaria through 
column chromatography on silica gel, Diaion HP-20, Sephadex H-20 and semipreparative 
HPLC. The subfractions were examined by H2SO4 solution spray on TLC for cardiac 
glycosides, which show as green spots, and subjected to a series of column chromatographic 
steps in order to obtain cardenolides/aglycones. The structures of new compounds were 
elucidated on the basis of spectroscopic methods, including 2D NMR techniques.
The HRFAB mass spectrum of 1 showed a molecular ion-related [M+H]+ peak at m/z 
567.2808, corresponding to the molecular formula C29H42O11. The NMR signals were due 
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to one methyl, eleven methylene, eight methine and six quaternary carbons as determined by 
DEPT 135 spectroscopy (Table 1). Compound 1 showed a UV absorption maximum at 216 
nm and IR absorption at 1734 cm −1 (γ-lactone carbonyl), which were indicative of a 
butenolactone system.13 The 1H NMR spectrum of 1 (Table 2) showed characteristic signals 
for a butenolactone ring at δH 4.98 and 5.27 (each 1H, d, J = 18.1 Hz, H-21a, and b) and 
6.08 (s, H-22), as well as a methyl singlet at δH 0.98 (s, H-18), suggesting 1 to be a 
cardenolide with a C-18 methyl group. A strong carbonyl absorption in the IR spectrum at 
1734 cm−1 and a carbon signal at δC 176.7 in the 13C NMR spectrum suggested that a 
carboxylic acid was present at C-19. Comparison of the 1H and 13C NMR spectra of 1 with 
those of antiaroside R (9),4 which was isolated from the n-BuOH soluble fraction, showed 
that the two structures were very similar, except for the differences in glycosidic signals and 
orientation at C-3. An anomeric proton signal at δH 6.08 (s) in the 1H NMR spectrum and 
signals at δC 99.8, 72.7, 72.8, 74.3, 69.9, and 18.6 in the 13C NMR spectrum indicated the 
presence of α-rhamnose. The α-orientation of C-3 was deduced from the coupling constant 
values of H-3 (dddd, J = 11.0, 11.0, 5.4, 5.4 Hz). This assignment was supported by 
downfield shifts of H-2a, H-3, and H-4a from δH 1.43 (m), 4.37 (br s, W1/2 = 15.7 Hz), and 
1.67 (d, J =12.7 Hz) in 9 to δH 2.19 (m), 4.81 (dddd, J = 11.0, 11.0, 5.4, 5.4 Hz), and 2.19 
(m) in 1. HMBC correlation of H-1′ with C-3 [δC 72.9/δH 6.08 (s)] inferred that the 
rhamnose unit was linked to C-3. Hence, the structure shown was established for 1 
(antiaritoxioside A).
A molecular formula of C28H42O10 was deduced for compound 2, 12 mass units less than 
that of periplorhamnoside (11).14 The 1H and 13C NMR data of the two compounds were 
similar except for the C-19 and C-10 signals. The carbon signal at δC 17.2 (C-19) in 11 was 
absent in 2. Furthermore, the carbon signal at δC 41.2 (C-10) in 11 was present at δC 74.4 
(C-10) in 2. Thus, both the NMR and MS data were indicative of a hydroxy rather than 
methyl group at C-10 in 2. The β-orientation of the C-3 monosaccharide unit was deduced 
from the W1/2 constant of H-3 (br s, W1/2 = 6.6 Hz). Therefore, the structure of 2 was 
determined as demethyl-10-hydroxy-periplorhamnoside and 2 was named antiaritoxioside B.
Compound 3 showed a pseudo molecular ion peak at m/z 539.2855 in its HRFABMS and 
had the same molecular formula, C28H42O10, as toxicarioside M (10),15 which was also 
isolated from the n-BuOH extract of this plant. The UV, IR and NMR data of 3 strongly 
resembled those of 10, consistent with a general structure containing a central cardenolide 
moiety dioxygenated at C-3, and C-5 and a hydroxy group in the 10-position. The sole 
significant differences were in certain glycosidic signals (Tables 1 and 2). An anomeric 
proton signal at δH 5.40 (d, J = 5.8 Hz) in the 1H NMR spectrum and signals at δC 99.3, 
72.2, 73.1, 73.8, 70.8, and 18.8 in the 13C NMR spectrum indicated the presence of β-
allomethylose. An NOE effect from H-1′ to H-3 suggested that the allomethylose unit was 
attached to C-3. These data agreed with the replacement of the antiarosyl unit in 10 by an 
allomethylosyl unit in 3. Thus, the structure of 3 was established for antiaritoxioside C.
A molecular formula of C28H43O11 was deduced for compound 4, 12 mass units less than 
that of β-antiarin (34),16 isolated from the CHCl3 soluble fraction. The 1H and 13C NMR 
data of the two compounds were similar except for the absence of a C-19 aldehyde group 
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and a downfield shift of C-10 from δC 55.0 in 34 to δC 74.7 in 4. These data suggested that 
the aldehyde group in 34 was replaced by a hydroxy group in 4. This conclusion was 
supported by 3JCH HMBC correlations from H-1b and H-11b to C-10. The β-orientations of 
the C-3 and -12 OH groups were deduced from the coupling constants of H-3 (δH 4.27, br. s, 
W1/2 = 7.9 Hz) and H-12 (δH 3.74, br t, J = 7.8 Hz). Thus, 4 was determined as 10-
hydroxy-19-nor-β-antiarin and named antiaritoxioside D.
Compound 5 had the same molecular formula, C28H43O11, as 4. The UV, IR and NMR data 
also strongly resembled those of 4, consistent with a structure containing a 19-nor-
cardenolide moiety tetraoxygenated at C-3, C-5, C-10 and C-12. The sole significant 
differences occurred in glycosidic signals of the molecules (Tables 1 and 2). The sugar 
proton signals of 5 indicated the presence of a β-antiarosyl moiety. These data were 
consistent with the replacement of the rhamnosyl unit in 5 by an antiarosyl unit in 5. The β-
orientations of C-3 and C-12 were deduced by the W1/2 of H-3 (br s, 7.7 Hz) and H-12 
coupling constant (br t, J = 9.7 Hz). Thus, the structure of 5 was assigned as shown, and 5 
was named antiaritoxioside E.
The HRFAB mass spectrum of 6 showed a molecular ion-related [M+Na]+ peak at m/z 
529.2774, corresponding to the molecular formula C28H42O8. The 1H and 13C NMR data 
(Tables 1 and 2) indicated that 6 was a 19-nor-cardenolide monosaccharide with a hexose 
sugar unit. Analyses of COSY, HMQC and HMBC spectra indicated that the sugar was α-
rhamnose. Comparison of the 1H and 13C NMR spectra of 6 with those of malayoside 
(29),3,16 showed that the two structures were very similar, except for that 6 did not contain 
the C-19 aldehyde group found in 29 based on the presence of a methine (−CH) proton at δH 
1.43 (m), upfield shift of C-10 from δC 51.2 to δC 34.0, and absence of CHO signals. 
Compound 6 was thus assigned to be 19-nor-malayoside and named antiaritoxioside F.
Compound 7 (C29H45O10) was 16 mass units larger than 11.14 The 1H/13C NMR spectra of 
7 and 11 were very similar, except for the sugar moiety signals and one oxygenated carbon 
in 7. The spectra of 11 showed a proton signal at δH 2.81 (dd, J = 8.9, 5.1 Hz) and a carbon 
signal at δC 51.4 (C-17), while in 7, the former signal was absent and the latter signal was 
replaced by an oxygenated carbon signal at δC 87.8 (C-17). Thus, an OH group was attached 
at C-17 in 7, and this postulate was supported by a downfield shift of C-16 from δC 27.35 in 
11 to δC 34.3 in 7, together with HMBC correlations of H-18 to C-17. An anomeric proton 
signal at δH 5.39 (d, J = 8.1 Hz) and carbon signals at δC 99.8, 69.6, 73.8, 73.7, 70.0, and 
17.3 indicated the presence of an antiarosyl moiety. An NOE effect between H-3 and H-1′ 
placed the antiarosyl unit on C-3, and a W1/2 coupling constant of 9.8 Hz for H-3 indicated 
α-orientation. Therefore, the structure 7 was established for antiaritoxioside G.
Compound 8 (C21H36O5) had 21 signals in the 13C NMR spectrum corresponding to two 
methyl, ten methylene, five methine, and four quaternary carbon atoms. The 1H and 13C 
NMR spectra of 8 displayed signals characteristic of the steroid skeleton of a cardenolide. 
However, the absence of typical signals for the olefinic group and carbonyl carbon of the 
butenolactone ring, suggested that the five-membered lactone in 8 was absent. This 
hypothesis was confirmed by the presence of a methylene group at δC 65.8/ δH 3.89 (1H, dd, 
J = 10.5, 6.1 Hz) and 4.08 (1H, dd, J = 10.5, 7.2 Hz, H-21) and one methine at δC 71.1/δH 
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4.36 (1H, dd, J = 7.2, 6.1 Hz, H-20), as well as the absence of any significant UV 
absorption. In addition to three OH groups on the steroid skeleton (C-3, C-5 and C-14), two 
OH groups were assigned at C-20 and C-21, based on carbon signals at δC 71.1 and 65.8, 
respectively. Orientation of the C-3 OH was also determined by the W1/2 of H-3 (br s, W1/2 
= 11.3 Hz). The above analysis established the structure of 8 as shown. This compound was 
reported as an intermediate in the synthesis of periplogenin by Peoghenghi et al.17 It has 
been isolated from a natural source for the first time and named antiarotoxinin B.
Compound 41 was obtained as colorless syrup, and its molecular formula was determined to 
be C15H18O6 on the basis of HREIMS ([M]+, m/z 294.1100). The IR spectrum showed 
absorption bands at 3400 and 1711 cm−1 for a hydroxyl group and α, β-unsaturated lactone, 
respectively. UV absorptions at 316 and 258 nm,18 and two AB type system protons at δH 
7.94 and 6.32 (each 1H, d, J = 9.6 Hz, H-4 & -3) suggested that 41 was a coumarin 
derivative.19 The 1H NMR spectrum of 41 also showed an aromatic proton at δH 7.06 (1H, 
s), three hydroxy protons at δH 9.60, 4.39 and 4.23 (each 1H, D2O exchangeable), one 
methoxy group at δH 3.79 (3H, s) and one 2,3-dihydroxyisopentyl group at δH 1.12 and 1.10 
(each 3H, s), 3.36 (1H, m), 2.95 (1H, d, J = 13.2 Hz) and 2.39 (1H, dd, J = 13.2, 10.4 Hz). 
The 13C NMR spectrum of 41 revealed the presence of 15 carbons resonances including two 
methyl, one methoxy, one methylene, four methine and seven quaternary carbons. 
Comparison of the 1H and 13C NMR spectra of 41 with those of skimminan, which was 
isolated from Skimmia anquetelia by Sharma et al.,20 showed that the two structures were 
very similar, except for the absence of signals for a sugar and one additional methoxy group 
(δH 3.79, δC 60.5) in the former. The HMBC spectrum showed correlations of the methoxy 
group at δH 3.79 with C-7 (δC 149.9) and of H-1′ (δH 2.95, and 2.39) with C-5 (δC 119.7), 
C-6 (δC 131.0) and C-7 (δC 149.9). Therefore, the methoxy group was attached at C-7 and 
the 2, 3-dihydroxyisopentyl moiety was located at C-6. This assignment was further 
confirmed by NOE effects between H-4 (δH 7.94) and H-5 (δH 7.06), as well as H-5 and 
H-1′ for 41. From the above data, new compound 41 was elucidated as 8-hydroxy-7-
methoxy-6-[2′, 3′-dihydroxyisopentyl]coumarin, and has been designated as anticarin A.
Compound 42,  +38.2° (c 0.25, MeOH), was isolated as colorless needles. The 
HRFABMS exhibited a pseudo-molecular ion at m/z 425.1367 for [M+H]+, consistent with 
the molecular formula C20H24O10. UV absorptions at 326, 302 (sh), 259, 247 and 220 (sh) 
nm,18 and IR band at 1709 (OC=O) cm−1, as well as two AB type protons at δH 7.96 (1H, d, 
J = 9.2 Hz, H-4) and 6.26 (1H, d, J = 9.2 Hz, H-3) suggested that 42 was a coumarin 
derivative.19 In the 1H NMR spectrum, the presence of two additional AB type protons at δH 
7.54 and 6.76 (each 1H, d, J = 8.8 Hz), two vicinal methine protons at δH 4.84 (1H, d, J = 
2.4 Hz) and 3.94 (1H, dd, J = 4.4, 2.4 Hz), and two methyl groups at δH 1.27 (6H, s), 
indicated that 42 was a khellactone glycoside.21 The signal at δH 4.84 was assigned as H-4′ 
based on its correlations to C-7 (δC 156.6), C-9 (δC 155.0), C-8 (δC 108.6), and C-1″ (δC 
103.8) in the HMBC spectrum, whereas the signal at δH 3.94 was assigned as H-3′ based on 
its correlation to C-3′ in the HMQC spectrum, as well as long range correlations of two 
methyl groups (δH 1.27) to C-3′ (δC 70.6). An anomeric proton signal at δH 4.71 (1H, d, J = 
8.0 Hz, H-1″) in the 1H NMR spectrum and signals at δC 103.8, 74.0, 76.8, 70.3, 77.3 and 
61.5 in the 13C NMR spectrum suggested the presence of β-glucose. The coupling constant 
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of the anomeric doublet (δH 4.71, 8.0 Hz) suggested a β-glucosidic linkage for the 
khellactone. The FAB-MS spectrum showed an ion fragment at m/z 263[M+-162], also 
indicating the presence of a hexose moiety. The β-glucose unit was placed at C-4′ on the 
basis of HMBC correlation between H-1″ of the glucose unit and C-4′ of the aglycone 
moiety, together with NOE correlation between H-1″ and H-4′. Accordingly, the structure of 
42 was established as 4′-β-glucosyl-khellactone, and 42 has been named anticarin B.
Compound 43 was obtained as colorless obtained as colorless needles. The molecular 
formula formula was established as C21H22O6 from m/z 370.1412 [M]+ in HREIMS. The IR 
spectrum of 43 showed absorption bands at 3456 and 3175 cm−1 for one or more hydroxy 
group(s) and 1638 cm−1 for a conjugated carbonyl functionality. The presence of a 
flavanone skeleton was evident from UV [226 (sh), 288, and 328 (sh) nm],18 and 1H [δH 
2.66 (1H, dd, J =17.2, 2.8 Hz, H-3α), 3.16 (1H, dd, J = 17.2, 13.2 Hz, H-3β) and 5.62 (1H, 
dd, J = 13.2, 2.8 Hz, H-2)] and 13C [δC 79.9 (C-2), 43.1 (C-3) and 197.4 (C-4)] NMR 
spectra. The 1H NMR spectrum further showed three hydroxy groups [δH 12. 17, 9.69 and 
7.55 (each 1H, s)], two singlet aromatic protons [δH 5.96 (2H, s)], AB system aromatic 
protons [δH 6.90 (1H, d, J =8.4 Hz) and 7.06 (1H, d, J = 8.4 Hz)], a methoxy moiety [δH 
3.86 (3H, s)], and an isoprenyl group [δH 1.67 (3H, s), 1.63 (3H, s), 3.52 (2H, d, J = 6.4 Hz) 
and 5.13 (1H, t, J = 6.4 Hz)]. The locations of these substituents were determined by HMQC 
and HMBC experiments. Based on 3J-correlations between the proton at δH 5.96 with C-5 
(δC 165.1), C-7(δC 167.2), and C-10 (δC 103.0) in the HMBC experiment and with C-6 in a 
HMQC spectrum, the singlet aromatic protons were assigned to H-6 and H-8, respectively, 
of ring-A HMBC correlations of the proton at δH 6.90 to C-1′ (δC 130.5) and C-3′ (δC 144.8) 
and at δH 7.06 to C-2 (δC 79.9) and C-2′ (δC 126.9) suggested that the AB system aromatic 
protons belonged H-5′ and H-6′, respectively. Combined with HMBC correlations of H-1″ 
(δH 3.52) to C-1′ (δC 130.5), C-2′ (δC 126.9), C-3′ (δC 144.8), and C-2″ (δC 124.0), and 
methoxy protons (δH 3.86) to C-4′ (δC 148.0) implied that the isoprenyl group was attached 
to C-2′, while the methoxy group was located at C-4′. These assignments were further 
confirmed by an NOE effect between the methoxy group and H-5′ (δH 6.90). Finally, a 
hydroxy group was attached to C-3′. The S-configuration of C-2 was determined by a 
positive Cotton effect observed at 312 nm and a negative one at 286 nm in the circular 
dichroism (CD) spectrum of 43.22 Based on these observations, 43 was established as 
(2S)-3′,5,8-trihydroxy-4′-methoxy-6,7-methylenedioxy-2′-prenylflavanone, and named 
antiarone L.
The molecular formula of 44 was determined as C25H26O6 from a molecular ion peak at m/z 
423.1733 [M+H]+ in its HRESIMS. The UV (324, 286, and 231 nm),18 1H, and 13C NMR 
spectra indicated that 44 was also a flavanone. The 1H and 13C NMR spectra of 44 closely 
resembled those of 43 except that signals for a 2,2-dimethylpyran ring unit were present at 
δH 6.40 (1H, d, J = 9.8 Hz, H-4″′), 5.73 (1H, d, J = 9.8 Hz, H-3″′), 1.20 and 1.18 (6H, s, 2″′-
CH3) and δC 122.7 (C-4″′), 131.3 (C-3″′), 77.5 (C-2″′), 29.1 & 32.4 (2″′-CH3) in 44, and the 
methoxy group found 43 was absent. Correlations of H-1″ [δH 3.48 (2H, d, J = 6.8 Hz)] to 
C-1′ (δC 130.1), C-2′ (δC 124.0) and C-3′ (δC 143.8) in the HMBC spectrum indicated an 
isoprenyl group was attached to C-2′, whereas long range correlations of H-4″′ (δH 6.40) to 
C-4′ (δC 140.5), C-5′ (δC 133.1) and C-6′ (δC 120.0) and of H-3″′ (δH 5.73) to C-5′ 
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suggested that the 2,2-dimethylpyran ring was fused to C-5′ and 4′. The absolute 
stereochemistry of 44 was deduced to be 2S because of a positive Cotton effect at 314 nm 
and a negative one at 290 nm in the circular dichroism (CD) spectrum of 44.22 Thus, the 
structure of compound 44 was assigned as (2S)-2″′,2″′-dimethylpyrano-3′,5,8-trihydroxy-2′-
prenylflavanone, and named antiarone K.
Antiaroside R (9),4 toxicarioside M (10),15 periplorhamnoside (11),14 antiaroside A (12),3 
peripalloside (13),14 cheiranthoside (14),23 strophanthidol (15),24 convallatoxal (16),16 
cannogenol (17),25 antiaroside B (18),3 strophanthidin (19),14 convallatoxin (20),16 
strophathojavoside (21),26 desglucocheirotoxin (22),24 strophalloside (23),14 convalloside 
(24),27 glucostrophalloside (25),28 cheirotoxin (26),29 antiaroside C (27),3 antiaroside D 
(28),3 malayoside (29),3,16 antiarigenin (30),14 α-antiarin (31),16 antialloside (32),26 
toxicarioside B (33),30 β-antiarin (34),16 antiaroside E (35),3 antiaroside F (36),3 antiaroside 
G (37),3 antiaroside H (38),3 antiaroside I (39),3 antiarotoxinin A (40),3 (+)-marmesin 
(45),31, decursinol (46),21 (R)-peucedanol (47),32 oxypeucedanin hydrate (48),33 (2S)-
pinocembrin (49),34 antiarones F (50),6 I (51),6 vanillic acid (52),35 p-hydroxybenzoic acid 
(53),36, vanillin (54),35 (3S,4R)-hydroxymellein (55),37 2, 4,6-trihydroxy-5-
methoxyactophenone (56),38 6-acetoxy-2,4-dihydroxyacetophenone (57),39 syringic aicd 
(58),40 koaburaside (59),41 vanilloyl β-D-glucose (60),42 uridine (61),43 xanthine (62),44 
adenosine (63),36 3-hydroxy-5-methoxybenzalacetophenone (64),45 and β-sitosterol (65)35 
were also isolated and identified by comparison of their physical and spectroscopic 
properties with those reported in the literature.
Cardenolides 11–40 and coumarins 41, 42, and 45 were assayed for anti-proliferative effects 
against 10 human cancer cell lines, KB, KB-VIN, A549, MCF-7, U-87-MG, PC-3, 1A9, 
CAKI-1, HCT-9, and S-KMEL-2.46 The cytotoxic data are shown in Table 3. Among the 
tested isolates, compounds 11, 12, 16, 17, 19–25, 29, 31–35, and 42 exhibited potent effects 
against all cancer cell lines. Among them, compounds 12, 16, 20, 22, and 31 showed ng/mL 
potency against one or more cancer cell lines. Compound 12 exhibited an ED50 of 0.0097 
μg/mL against KB cancer cell lines. Compound 16 demonstrated ED50 values of 0.0040, 
0.0076, and 0.0061 μg/mL against A549, 1A9 and CAKI-1 cells, respectively. Compound 
20 showed ED50 values of 0.0027, 0.0065, 0.0031, 0.0014 and 0.0013 μg/mL against A549, 
MCF-7, CAKI-1, HCT-9 and s-KMEL-2 cells, respectively. Compound 22 exhibited an 
ED50 of 0.0092 μg/mL against A549 cells. Finally, compound 31 showed an ED50 of 0.0044 
μg/mL against PC-3 cells. Common structural features in all five compounds included a 5β-
OH, 13β-Me, 14β-OH, and 17β-α, β-unsaturated-γ-butyrolactone. Compounds 20, 22, and 
31 contained a C-18 β-CHO, while 12 and 16 contained β-CH3 and −CH2OH, respectively. 
Compound 31 contained a C-12 β-OH, while compounds 12, 16, 20, and 22 were 
unsubstituted. All five compounds contained a 3β-sugar moiety, 3β-O-β-D-antiarose in 12, 
22, and 31, 3β-O-α-L-rhamnose in 16 and 20.
The following specific structure-activity correlations were noted in these studies. Changing 
the orientation of the glycoside from 3β in potent cardenolide 20 to 3α in 27 significantly 
decreased the cytotoxicity, for example, from 0.0027 to 0.48 μg/mL against A549, from 
0.0065 to 1.4 against MCF-7, from 0.0031 to 0.31 μg/mL against CAKI-1, from 0.0014 to 
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1.5 μg/mL against HCT-9, and from 0.0013 to 0.26 μg/mL against s-KMEL-2. Compound 
28 with a 3α-diglycoside was also one of the least potent cardenolides. Activity decreased 
dramatically when the 3β-O-α-L-rhamnose of 16 (ED50 values 0.0.0040–0.036 μg/mL) was 
changed to 3β-OH in 15 (ED50 values 0.14–6.5 μg/mL). Replacement of the C-10 CH3 of 12 
with COOH in 38 together with addition of a 12β-OH decreased cytotoxicity from 0.0097 to 
5.9 μg/mL against KB cells. Similarly, changing the C-10 CH2OH of 16 to H in 39 
decreased cytotoxicity from 0.0040 to 0.36 μg/mL against A549 cells. Compounds showing 
the lowest potency against the cancer cell lines included 14, 15, 27, and 28 with ED50 values 
ranging from 0.12 to 4.2 μg/mL, as well as 30 and 36–40 with ED50 values of 0.36–17.5 
μg/mL. Notably, a C-10 COOH, COO-glucose, or H was found in 36–39 rather than CHO, 
CH3, or CH2OH as found in the more potent compounds. While the cytotoxic effects of new 
compounds 1–6 were not examined in this report,46 the cytotoxic effects of structurally 
similar cardiac glycosides have been reported.4,10 Our observations were generally 
consistent with the prior findings (for example, compound 9 with COO-glucose at C-10 and 
compounds with α-oriented substituents at C-3 exhibited lower cytotoxicity).4 In summary, 
from our investigation, the β-orientation of C-3, C-3 monosaccharide, and C-10 substituents 
(CHO, CH3, or CH2OH) are crucial factors in the cytotoxicity effects of cardiac glycosides. 
Prior reports also indicated that compounds with C-10 OH may exhibit significant 
cytotoxicity.10
Among the three tested coumarins, compound 41 and the structurally related linear 
dihydrofuranocoumarin 45 showed no cytotoxic activity, whereas the angular 
dihydropyranocoumarin 42 exhibited broad and significant cytotoxicity against KB-VIN, 
A549, MCF-7, PC-3, 1A9, CAKI-1 and S-KMEL-2 cell lines with ED50 values ranging 
from 1.2 to 4.1 μg/mL.
It is a definite possibility that the structurally similar cardiac glycoside metabolites were 
derived biogenetically from a general catabolic process. A possible biogenetic 
transformation pathway is presented in Scheme 1 for the first time on the basis of evidence 
from natural sources. The proposed biosynthesis could explain the catabolic progression of 
structurally interesting cardiac glycosides.
3. Conclusions
In summary, this paper described the isolation and structure elucidation of 12 new 
compounds, including eight cardiac glycosides/aglycones, antiaritoxiosides A-G (1–7) and 
antiarotoxinin B (8), two coumarins, anticarin A–B, and two flavanones, antiarones L–K. 
The cytotoxic activity of cardiac glycosides and coumarins against ten cancer cell lines also 
reported. Compounds 12, 16, 20, 22, and 31 showed significant cytotoxicity against all 10 
cancer cell lines, with notable potency at the ng/mL level against some cell lines. SAR 
correlations were also identified. While many cardiac glycosides are reported in the 
literature, compounds with 10-carboxy (e.g., 1, 9) and 3α-hydroxy (e.g., 1) substituents are 
rare. Furthermore, the C-10 substituents, including COOH, CHO, CH2OH, CH3, OH and H, 
of cardiac glycosides can help to explain the catabolic progression of structurally interesting 
cardiac glycosides.
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Optical rotations were measured with a JASCO DIP-370 polarimeter. IR spectra were 
determined as KBr discs on a Shimazu FTIR-8501 spectrophotometer. UV spectra were 
acquired on a Hitachi UV-3210 spectrophotometer. The 1H and 13C NMR spectra were 
recorded on Bruker Avance 300 (1H at 300 MHz) and AMX 400 (1H at 400 MHz) 
spectrometers. The 1H and 13C chemical shifts (ppm) were referenced to the solvent peaks 
for pyridine-d5 at δH 8.71 and δC 149.9, DMSO-d6 at δH 2.49 and δC 39.5, acetone-d6 at δH 
2.05 and δC 29.9, 206.7, and methanol-d4 at δH 3.31 and δC 49.0. ESIMS, FABMS and 
HRMS were taken with a VG 70–250 S spectrometer by direct inlet system. Merck silica gel 
60 (Merck 70–230, 230–400 mesh) was used for column chromatography. Glass sheets of 
silica gel 60 F254 (Merck 0.2 mm thick) were used for TLC Melting points were measured 
on a Yanagimoto MP-S3 micromelting point apparatus and are uncorrected.
4.2. Plant material
Trunk bark of A toxicaria was collected from Yunnan, China, and authenticated by C.S. 
Kuoh (Department of Life Sciences, National Cheng Kung University, Tainan, Taiwan). A 
voucher specimen (NCKUWu 92012) has been deposited in the Herbarium of National 
Cheng Kung University, Tainan, Taiwan, R.O.C.
4.3. Extraction and isolation
Trunk bark of A toxicaria (6.0 kg) was cut into small pieces and extracted with 95% EtOH 
(20 L × 3). Evaporation of the solvent under reduced pressure provided 239.0 g of crude 
extract, which was partitioned between CHCl3−H2O, and n-BuOH−H2O, successively, to 
yield CHCl3 (AT-C, 65.1 g), n-BuOH (AT-B, 100.2 g), and H2O (AT-W, 73.7 g) fractions. 
The CHCl3 fraction was subjected to silica gel CC using increasing polarity mixtures of n-
hexanes-acetone as eluant to give 14 fractions (AT-C-1 ∼ 14). AT-C-2 was recrystallized to 
obtain 65 (42.5 mg). AT-C-3 was chromatographed on silica gel using n-hexane–diisopropyl 
ether (3:1) to obtain 56 (1.2 mg), 57 (1.7 mg), and 64 (11.5 mg). AT-C-4 was 
chromatographed on silica gel using n-hexane–diisopropyl ether (3:1) to obtain 43 (12.4 
mg), 49 (3.1 mg), 50 (10.0 mg), 51 (175.4 mg), 55 (1.2 mg), and 64 (2.4 mg). AT-C-5 was 
chromatographed on silica gel eluted with n-hexane–diisopropyl ether (1:1) to give 43 (18.0 
mg), 44 (1.0 mg), 49 (3.7 mg), 50 (17.1 mg), and 55 (2.4 mg). AT-C-6 was 
chromatographed on silica gel using diisopropyl ether−MeOH (40:1) to obtain 7 (8.7 mg), 
19 (103.2 mg), 46 (3.1 mg), 52 (8.7 mg), 54 (12.3 mg), and 65 (12.5 mg). AT-C-7 was 
chromatographed on silica gel and eluted with n-hexane–diisopropyl ether (1:1) to give 15 
(6.6 mg) and 21 (7.0 mg). AT-C-8 was chromatographed on silica gel using EtOAc−MeOH 
(20:1) to obtain 6 (2.1 mg), 8 (19.6 mg), 17 (3.2 mg), 29 (8.8 mg), 35 (37.6 mg), and 39 (7.5 
mg). AT-C-9 and 10 were chromatographed on silica gel using EtOAc−MeOH (20:1) to 
obtain 29 (21.4 mg), and 20 (117.2 mg), respectively.
The n-BuOH fraction was subjected to Diaion HP-20 CC eluting with a H2O−MeOH 
gradient system to give 12 fractions (AT-B-1 ∼ 12). AT-B-4 and 5 were chromatographed 
on silica gel using CHCl3−MeOH (9:1) to obtain 4 (1.3 mg), 5 (1.5 mg), 30 (58.9 mg), 31 
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(11.0 mg), 32 (4.3 mg), 34 (7.3 mg), 37 (34.7 mg), 38 (147.4 mg), 52 (10.0 mg), 53 (10.2 
mg), and 54 (5.5 mg), successively. AT-B-6 was chromatographed on silica gel using 
CHCl3−MeOH (9:1) to obtain 31 (118.4 mg). AT-B-7 and 8 were chromatographed on silica 
gel using CHCl3−MeOH−H2O (9:1:005) to obtain 1 (3.0 mg), 2 (3.8 mg), 10 (0.5 mg), 14 
(9.1 mg), 16 (6.1 mg), 18 (12.3 mg), 20 (431.2 mg), 22 (4.3 mg), 23 (5.9 mg), 24 (91.2 mg), 
25 (18.3 mg), 26 (0.5 mg), 27 (112.3 mg), 28 (12.2 mg), 36 (5.9 mg), 41 (25.3 mg), 42 (5.8 
mg), 47 (6.7 mg), and 58 (2.7 mg), successively. AT-B-9 and 10 were chromatographed on 
silica gel using CHCl3−MeOH−H2O (9:1:0.05) to obtain 3 (0.3 mg), 11 (10.9 mg), 12 (9.8 
mg), 13 (1.9 mg), 20 (12.5 mg), 22 (29.9 mg), 23 (17.8 mg), 33 (13.5 mg), 40 (0.7 mg), 45 
(1.2 mg), 48 (0.9 mg), and 53 (2.8 mg), successfully.
The H2O fraction was subjected to Diaion HP-20 CC eluting with a H2O−MeOH gradient 
system to give 10 fractions (AT-W-1 ∼ 10). AT-W-2 and 3 were chromatographed on silica 
gel using EtOAC−MeOH−H2O (4:1:0.5) to obtain 61 (2.3 mg), and 62 (10.7 mg). AT-W-4 
was chromatographed on silica gel using EtOAC−MeOH−H2O (4:1:0.5) to obtain 59 (22.4 
mg), 60 (29.0 mg), and 63 (1.2 mg). AT-W-5 was chromatographed on silica gel using 
CHCl3−MeOH−H2O (4:1:0.005) to obtain 59 (12.6 mg). AT-W-6 and 7 was 
chromatographed on silica gel using EtOAC−MeOH−H2O (4:1:0.5) to obtain 58 (17.3 mg). 
AT-W-8 and 9 were chromatographed on Sephadex LH-20 using a H2O−MeOH gradient 
system to obtain 9 (0.7 mg), 20 (43.2 mg), 24 (26.8 mg), 28 (26.4 mg), 31 (20.2 mg) and 32 
(1.3 mg), successfully.
4.4. Antiaritoxioside A (1)
Colorless syrup;  +189.13° (c 0.01 in MeOH); UV λmax (MeOH)/nm (log ε) 216 (4.21); 
IR νmax/cm−1 (KBr) 3400, 2930, 1734, 1651, 1506, 1456, 1394, 1229, 1026; 1H NMR data 
(pyridine-d5) see Table 2; 13C NMR data (pyridine-d5) see Table 1; FABMS m/z 567 (13%) 
[M+H]+; HRFABMS m/z 567.2808 (C29H43O11 [M+H]+ requires 567.2805).
4.5. Antiaritoxioside B (2)
Colorless syrup;  −9.52° (c 0.04 in MeOH); UV λmax(MeOH)/nm (log ε) 215 (4.31); IR 
νmax/cm−1 (KBr) 3440, 2937, 1744, 1647, 1634, 1454, 1032; 1H NMR data (pyridine-d5) 
see Table 2; 13C NMR data (pyridine-d5) see Table 1; FABMS m/z 539 (8%) [M+H]+; 
HRFABMS m/z 539.2855 (C28H43O10 [M+H]+ requires 539.285).
4.6. Antiaritoxioside C (3)
Colorless syrup;  −242.2° (c 0.003 in MeOH); UV λmax (MeOH)/nm (log ε) 213 (4.14); 
IR νmax/cm−1 (KBr) 3410, 2928, 1734, 1647, 1636, 1541, 1456, 1076, 1036; 1H NMR data 
(pyridine-d5) see Table 2; 13C NMR data (pyridine-d5) see Table 1; FABMS m/z 539 (6%) 
[M+H]+; HRFABMS m/z 539.2855 (C28H43O10 [M+H]+ requires 539.2856).
4.7. Antiaritoxioside D (4)
Colorless syrup;  −45.88° (c 0.01 in MeOH); UV λmax (MeOH)/nm (log ε) 214 (4.17); 
IR νmax/cm−1 (KBr) 3410, 2932, 1742, 1649, 1454, 1377, 1029; 1H NMR data (pyridine-d5) 
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see Table 2; 13C NMR data (pyridine-d5) see Table 1; FABMS m/z 555 (3%) [M+H]+; 
HRFABMS m/z 555.2805 (C28H43O11 [M+H]+ requires 555.2805).
4.8. Antiaritoxioside E (5)
Colorless syrup;  −69.72° (c 0.02 in MeOH); UV λmax (MeOH)/nm (log ε) 271 (3.63), 
218 (4.36); IR νmax/cm−1 (KBr) 3410, 2945, 1732, 1640, 1630, 1452, 1385, 1171, 1109, 
1078,1028, 997; 1H NMR data (pyridine-d5) see Table 2; 13C NMR data (pyridine-d5) see 
Table 1; FABMS m/z 555 (8%) [M+H]+; HRFABMS m/z 555.2802 (C28H43O11 [M+H]+ 
requires 555.2805).
4.9. Antiaritoxioside F (6)
Colorless syrup;  −15.28° (c 0.02 in MeOH); UV λmax (MeOH)/nm (log ε) 216 (4.32); 
IR νmax/cm−1 (KBr) 3410, 2926, 1742, 1645, 14474, 1377, 1049; 1H NMR data (pyridine-
d5) see Table 2; 13C NMR data (pyridine-d5) see Table 1; FABMS m/z 529 (7%) [M+Na]+, 
507 (5%) [M+H]+; HRFABMS m/z 529.2774 (C28H42-NaO8 [M+Na]+ requires 529.2777).
4.10. Antiaritoxioside G (7)
Colorless powder (CHCl3−MeOH); mp 227–228 °C;  −57.69° (c 0.01 in MeOH); UV 
λmax (MeOH)/nm (log ε) 215 (4.62); IR νmax/cm−1 (KBr) 3350, 2949, 1753, 1383, 1286, 
1175, 1101, 1022, 991; 1H NMR data (pyridine-d5) see Table 2; 13C NMR data (pyridine-
d5) see Table 1; FABMS m/z 553 (2%) [M+H]+; HRFABMS m/z 553.3014 (C29H45O10 [M
+H]+ requires 553.3012).
4.11. Antiarotoxinin B (8)
Colorless powder (CHCl3−MeOH); mp >280 °C;  −31.34° (c 0.02 in MeOH); IR 
νmax/cm−1 (KBr) 3261, 2936, 2882, 1470, 1448, 1383, 1088, 1047; 1H NMR data (pyridine-
d5) see Table 2; 13C NMR data (pyridine-d5) see Table 1; EIMS m/z 368 (8%) [M]+, 350 
(28%), 319 (39%), 301 (41%), 296 (100%), 290 (15%), 283 (20%), 272 (14%), 147 (12%), 
121 (15%), 107 (28%), 97 (39%); HREIMS m/z 368.2560 (C21H36O5 [M]+ requires 
368.2563).
4.12. Anticarin A (41)
Colorless syrup;  +16.3° (c 0.058, MeOH); UV λmax (MeOH)/nm (log ε) 316 (3.60), 
258 (3.48); IR νmax/cm−1 (KBr) 3400, 2926, 1711, 1607, 1572, 1450, 1279; 1H NMR (400 
MHz, DMSO-d6) δH 9.60 (1H, br s, D2O exchangeable, OH), 7.94 (1H, d, J = 9.6 Hz, H-4), 
7.06 (1H, s, H-5), 6.32 (1H, d, J = 9.6 Hz, H-3), 4.39 (1H, d, J = 6.0 Hz, D2O exchangeable, 
2′-OH), 4.23 (1H, br s, D2O exchangeable, 3′-OH), 3.79 (3H, s, OCH3), 3.36 (1H, m, H-2′), 
2.95 (1H, d, J = 13.2 Hz, H-1′), 2.39 (1H, dd, J = 13.2, 10.4 Hz, H-1′), 1.12 (3H, s, H-4′), 
1.10 (3H, s, H-5′); 13C NMR (100 MHz, DMSO-d6) δC 160.3 (C-2), 149.9 (C-7), 145.0 
(C-4), 142.3 (C-9), 137.2 (C-8), 131.0 (C-6), 119.7 (C-5), 115.0 (C-10), 114.0 (C-3), 77.8 
(C-2′), 71.9 (C-3′), 60.5 (OCH3), 31.4 (C-1′), 26.6 (C-5′), 24.8 (C-4′); EIMS m/z 294 (28%) 
[M]+, 261 (7%), 236 (79%), 235 (37%), 221 (23%), 205 (100%), 193 (56%), 177 (20%), 
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163 (25%), 147 (22%), 59 (84%); HREIMS m/z 294.1100 (C15H18O6 [M]+ requires 
294.1103).
4.13. Anticarin B (42)
Colorless needles (MeOH); mp. 265–267 °C;  +38.2° (c 0.2523, MeOH); UV λmax 
(MeOH)/nm (log ε) 326 (4.18), 302 (3.92, sh), 259 (3.46), 247 (3.50), 220(4.13, sh), 204 
(4.67); IR νmax/cm−1 (KBr) 3300, 1709, 1605, 1592, 1541, 1306, 1126, 1076, 1036; 1H 
NMR (400 MHz, DMSO-d6) δH 7.96 (1H, d, J = 9.2 Hz, H-4), 7.54 (1H, d, J = 8.8 Hz, H-5), 
6.76 (1H, d, J = 8.8 Hz, H-6), 6.26 (1H, d, J = 9.2 Hz, H-3), 5.29 (1H, d, J = 4.4 Hz, D2O 
exchangeable, 3′-OH), 4.93 (2H, m, D2O exchangeable, 3″, 4″-OH), 4.84 (1H, br. d, J = 2.4 
Hz, H-4′), 4.71 (1H, d, J = 8.0 Hz, H-1″), 4.52 (1H, br s, D2O exchangeable, 4′-OH), 4.42 
(1H, t, J = 6.0 Hz, D2O exchangeable, 6″-OH), 3.94 (1H, dd, J = 4.4, 2.4 Hz, H-3′), 3.76 
(1H, br. dd, J = 12.0, 6.0 Hz, H-6″), 3.50 (1H, br s dd, J = 12.0, 6.0 Hz, H-6″), 3.25 (1H, m, 
H-5″), 3.22 (1H, t, J = 8.4 Hz, H-3″), 3.05 (1H, m, H-4″), 2.90 (1H, t, J = 8.4 Hz, H-2″), 
1.27 (6H, s, 20-CH3 × 2); 13C NMR (100 MHz, DMSO-d6) δC 160.1 (C-2), 156.6 (C-7), 
155.0 (C-9), 144.8 (C-4), 129.1 (C-5), 114.1 (C-6), 112.0 (C-3, 10), 108.6 (C-8), 103.8 
(C-1″), 78.5 (C-2′), 77.3 (C-5″), 76.8 (C-3″), 74.0 (C-2″), 71.4 (C-4′), 70.6 (C-3′), 70.3 
(C-4″), 61.5 (C-6″), 24.9 & 24.3 (2′-CH3 × 2); FABMS m/z 425 (23%) [M+H]+, 371 (8%), 
307 (10%), 263 (75%), 245 (31%), 219 (74%), 154 (100%), 136 (86%); HRFABMS m/z 
425.1367 (C20H25O10 [M+H]+ requires 425.1369).
4.14. Antiarone L (43)
Colorless needles (acetone); mp. 131–133°C;  −3.0° (c 0.53, MeOH); UV λmax 
(MeOH)/nm (log ε) 328 (3.63, sh), 288 (4.31), 226 (4.44, sh), 206 (4.86); IR νmax/cm−1 
(KBr) 3456, 3175, 2964, 2924, 1638, 1605, 1497, 1460, 1375, 1277, 1163, 1082; CD (c 5.4 
× 10−5, MeOH) [θ]208 −9580, [θ]224 +38450, [θ]286 −22450, [θ]312 +52330; 1H NMR (400 
MHz, acetone-d6) δH 12.17 (1H, br s, D2O exchangeable, 5-OH), 9.69 (1H, br s, D2O 
exchangeable, 8-OH), 7.55 (1H, br s, D2O exchangeable, 3′-OH), 7.06 (1H, d, J =8.4 Hz, 
H-60), 6.90 (1H, d, J = 8.4 Hz, H-5′), 5.96 (2H, s, H-6&8), 5.62 (1H, dd, J = 13.2, 2.8 Hz, 
H-2), 5.13 (1H, t, J = 6.4 Hz, H-2″), 3.86 (3H, s, OCH3), 3.52 (2H, d, J = 6.4Hz, H-1″), 3.16 
(1H, dd, J = 17.2, 13.2 Hz, H-3α), 2.66 (1H, dd, J = 17.2, 2.8 Hz, H-3β), 1.67&1.63 (each 
3H, s, H-4″&5″); 13C NMR (acetone-d6, 100 MHz) δC 197.4 (C-4), 167.2 (C-7), 165.1 
(C-5), 164.4 (C-9), 148.0 (C-4′), 144.8 (C-3′), 131.4 (C-3″), 130.5 (C-1′), 126.9 (C-2′), 
124.0 (C-2″), 118.2 (C-6′), 109.5 (C-5′), 103.0 (C-10), 96.7 (C-8), 95.7 (C-6), 79.9 (C-2), 
56.2 (OCH3), 43.1 (C-3), 25.7 & 17.9 (C-4″ & 5″), 25.0 (C-1″); EIMS m/z 370 (100%) 
[M]+, 352 (10%), 219 (12%), 153 (26%), 125 (18%); HREIMS m/z 370.1412 (C21H22O6 
[M]+ requires 370.1416).
4.15. Antiarone K (44)
Colorless powder (acetone); mp 171–173 °C;  −44.7° (c 0.001, MeOH); UV λmax 
(MeOH)/nm (log ε) 324 (3.41, sh), 286 (4.06), 231 (4.35, sh), 213 (4.25); IR νmax/cm−1 
(KBr) 3600–3000, 2963, 2926, 2855, 1639, 1522, 1466, 1456, 1340, 1271, 1161, 1085; CD 
(c 5.0 × 10−5, MeOH) [θ]210 −10580, [θ]229 +39460, [θ]290 −25380, [θ]314 +52190; 1H 
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NMR (acetone-d6, 400 MHz) δH 12.18 (1H, br s, D2O exchangeable, 5-OH), 7.70 (1H, br s, 
D2O exchangeable, 3′-OH), 6.56 (1H, s, H-6′), 6.40 (1H, d, J = 9.8 Hz, H-1″′), 5.95 (2H, s, 
H-6 & 8), 5.73 (1H, d, J = 9.8 Hz, H-2″′), 5.60 (1H, dd, J = 13.4, 2.6 Hz, H-2), 5.13 (1H, t, J 
= 6.8 Hz, H-2″), 3.48 (2H, d, J = 6.8 Hz, H-1″), 3.17 (1H, dd, J = 17.0, 13.4Hz, H-3α), 2.64 
(1H, dd, J = 17.0, 2.6 Hz, H-3β), 1.63&1.67 (each 3H, s, H-4″&5″), 1.18 & 1.20 (each 3H, 
s, 2″′-CH3 × 2); 13C NMR (acetone-d6, 100 MHz) δC 197.4 (C-4), 167.2 (C-7), 165.2 (C-5), 
164.5 (C-9), 143.8 (C-3′), 140.5 (C-4′), 133.1 (C-5′), 131.3 (C-3″ & 3″′), 120.1 (C-1′), 127.1 
(C-2′), 124.0 (C-2″), 122.7 (C-4″′), 120.0 (C-6′), 103.0 (C-10), 96.7 (C-8), 95.7 (C-6), 77.5 
(C-2″′), 77.0 (C-2), 43.2 (C-3), 32.4 & 29.1 (C-2″′-CH3 × 2), 25.7&17.9 (C-4″& 5″), 25.2 
(C-1″); EIMS m/z 436 (100%) [M]+; 418 (10%), 286 (25%), 255 (18%); 153 (26%); 
HREIMS m/z 436.1889 (C26H28O6 [M]+ requires 436.1886).
4.16. In vitro cytotoxicity assay
The sulforhodamine B assay was used according to the procedures developed and validated 
at NCI.47 Doxorubicin was used as the positive control antitumor drug. The in vitro 
anticancer activities are expressed as ED50 values, which is the test compound concentration 
(μg/mL) that reduced the cell number by 50% after 72 h of continuous treatment. The values 
were interpolated from dose-response data. Each test was performed in triplicate with 
variation less than 5%. The ED50 values determined in each of independent tests varied less 
than 10%. Compound stock solutions were prepared in DMSO with the final solvent 
concentration ≤ 1% DMSO (v/v), a concentration without effect on cell replication. The 
cells were cultured at 37 °C in RPMI-1640 supplemented with 25 mM N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), 2% (w/v) sodium bicarbonate, 
10% (v/v) fetal bovine serum, and 100 μg/mL kanamycin in a humidified atmosphere 
containing 5% CO2.
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